|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1776 Wilson Blvd. |
Address2 | Suite 200 |
City | Arlington |
State | VA |
Zip Code | 22209 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 26672-12
|
||||||||
|
6. House ID# 302390000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Heidi Ecker |
Date | 4/16/2020 8:52:06 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
H.R. 5 Equality Act of 2019
S. 788 Equality Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Callen |
|
|
|
Steve |
Anderson |
|
|
|
Tom |
O'Donnell |
|
|
|
William |
Tighe |
|
|
|
Vonnie |
Hampel |
|
|
|
Amber |
Manko |
|
|
|
Kevin |
Nicholson |
|
|
|
Heidi |
Ecker |
|
|
|
Evan |
Sarris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act
S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act
S.340 CREATES Act of 2019
H.R. 985 FAST Generics Act of 2019
S.640 Phair Pricing Act of 2019
S. 97 Affordable and Safe Prescription Drug Importation Act
S. 61 Safe and Affordable Drugs from Canada Act of 2019
H.R. 1034 Phair Pricing Act of 2019
H.R. 965 CREATES Act of 2019
H.R. 1478 Affordable Insulin Act of 2019
H.R. 447 Affordable and Safe Prescription Drug Importation Act
H.R. 1499 Protecting Consumer Access to Generic Drugs Act
H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019
H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019
H.R. 1607 Fairness to Pet Owners Act
H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act
H.R. 478 Safe and Affordable Drugs from Canada Act of 2019
H.R. 3 Lower Drug Costs Now Act of 2019
H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448 Medicare Drug Price Negotiation Act
H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019
H.R. 5304 PBM Transparency in Prescription Drug Costs Act
H.R. 5172 NOPAIN Act
S. 2543 Prescription Drug Pricing Reduction Act of 2019
S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019
S. 2247 Phair Relief Act of 2019
S. 3070 Preventing Pill Mills Through Data Sharing Act
H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019
H.R. 19 Lower Costs, More Cures Act on 2019
S. 3129 Lower Costs, More Cures Act on 2019
H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Callen |
|
|
|
Steve |
Anderson |
|
|
|
Tom |
O'Donnell |
|
|
|
William |
Tighe |
|
|
|
Vonnie |
Hampel |
|
|
|
Amber |
Manko |
|
|
|
Kevin |
Nicholson |
|
|
|
Heidi |
Ecker |
|
|
|
Evan |
Sarris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes
S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes
S. 3070 Preventing Pill Mills Through Data Sharing Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Callen |
|
|
|
Steve |
Anderson |
|
|
|
Tom |
O'Donnell |
|
|
|
William |
Tighe |
|
|
|
Vonnie |
Hampel |
|
|
|
Amber |
Manko |
|
|
|
Kevin |
Nicholson |
|
|
|
Heidi |
Ecker |
|
|
|
Evan |
Sarris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
H.R. 1607 Fairness to Pet Owners Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Callen |
|
|
|
Tom |
O'Donnell |
|
|
|
Amber |
Manko |
|
|
|
Vonnie |
Hampel |
|
|
|
William |
Tighe |
|
|
|
Steve |
Anderson |
|
|
|
Kevin |
Nicholson |
|
|
|
Evan |
Sarris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448 Medicare Drug Price Negotiation Act
H.R. 1046 Medicare Negotiation and Competive Licensing Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Callen |
|
|
|
Heidi |
Ecker |
|
|
|
William |
Tighe |
|
|
|
Tom |
O'Donnell |
|
|
|
Vonnie |
Hampel |
|
|
|
Amber |
Manko |
|
|
|
Steve |
Anderson |
|
|
|
Kevin |
Nicholson |
|
|
|
Evan |
Sarris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 3 Lower Drug Costs Now Act of 2019
H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019
H.R. 448 Medicare Drug Price Negotiation Act
H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019
H.R. 5304 PBM Transparency in Prescription Drug Costs Act
H.R. 5172 NOPAIN Act
S. 2543 Prescription Drug Pricing Reduction Act of 2019
H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Callen |
|
|
|
Heidi |
Ecker |
|
|
|
Kevin |
Nicholson |
|
|
|
Tom |
O'Donnell |
|
|
|
Steve |
Anderson |
|
|
|
William |
Tighe |
|
|
|
Vonnie |
Hampel |
|
|
|
Amber |
Manko |
|
|
|
Evan |
Sarris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 5430 United States-Mexico-Canada Agreement Implementation Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Callen |
|
|
|
Steve |
Anderson |
|
|
|
Tom |
O'Donnell |
|
|
|
Vonnie |
Hampel |
|
|
|
Amber |
Manko |
|
|
|
Heidi |
Ecker |
|
|
|
Kevin |
Nicholson |
|
|
|
William |
Tighe |
|
|
|
Evan |
Sarris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Callen |
|
|
|
Steve |
Anderson |
|
|
|
Tom |
O'Donnell |
|
|
|
William |
Tighe |
|
|
|
Vonnie |
Hampel |
|
|
|
Amber |
Manko |
|
|
|
Heidi |
Ecker |
|
|
|
Kevin |
Nicholson |
|
|
|
Evan |
Sarris |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |